Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New intraocular lens technology.

Randall J Olson1, Liliana Werner, Nick Mamalis

  • 1Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, Utah 84132, USA. randall.olson@hsc.utah.edu

American Journal of Ophthalmology
|July 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimated Medicare Part D Ocular Drug Savings with a Direct-to-Consumer Pharmacy.

Ophthalmology·2026
Same author

Real-world data on toxic anterior segment syndrome.

Journal of cataract and refractive surgery·2026
Same author

Long-Term Implant Cytology Evaluation of Explanted Intraocular Lenses Manufactured from Different Materials.

Journal of cataract and refractive surgery·2026
Same author

Assessment of calcification presence in hydrophilic acrylic phakic intraocular lenses.

Journal of cataract and refractive surgery·2026
Same author

Comment on: Intraocular ointment after phacoemulsification.

Journal of cataract and refractive surgery·2025
Same author

Unanswered questions regarding the pathogenesis of late onset posterior capsular opacification.

Frontiers in ophthalmology·2025

Phakic intraocular lenses (IOLs) and presbyopia treatments are advancing, with new options like blue-light filtering IOLs emerging. However, unresolved issues regarding safety and efficacy require further investigation.

Area of Science:

  • Ophthalmology
  • Biomedical Engineering

Background:

  • Phakic intraocular lenses (IOLs) offer refractive correction for various visual impairments.
  • Presbyopia treatment involves intraocular lens (IOL) technologies to restore near vision.
  • Age-related macular degeneration (ARMD) is a leading cause of vision loss, with blue light exposure as a potential risk factor.

Purpose of the Study:

  • To review the current status of phakic intraocular lenses (IOLs).
  • To examine intraocular treatments for presbyopia.
  • To assess IOLs designed to filter blue light for potential ARMD risk reduction.

Main Methods:

  • Comprehensive review of current scientific literature.
  • Medline and internet search engines utilized for data retrieval.
  • Focused search on phakic IOLs, presbyopia/multifocal IOLs, and blue light/ARMD.

Related Experiment Videos

Main Results:

  • An iris-fixated phakic IOL is US-approved, with noted concerns for corneal health and dislocation.
  • Anterior and posterior chamber phakic IOLs present risks including cataract formation and pigment dispersion.
  • Intraocular presbyopia treatments (monovision, multifocal, accommodative IOLs) lack a clear superior option.
  • Blue-light filtering IOLs show presumptive evidence for ARMD risk reduction, but definitive studies are lacking.

Conclusions:

  • The field of IOLs is rapidly evolving with diverse new options.
  • Phakic IOLs and presbyopia correction are increasingly significant in ophthalmology, yet challenges remain.
  • Blue-light filtering IOLs may become standard if stronger evidence links blue light to ARMD progression.